Welcome!

News Feed Item

Trichotillomania Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

Trichotillomania Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trichotillomania Global Clinical Trials Review, H2, 2014" provides data on the Trichotillomania clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trichotillomania. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trichotillomania. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Trichotillomania 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in North America 8
Top Countries Contributing to Clinical Trials in Middle East and Africa 9
Top Countries Contributing to Clinical Trials in Central and South America 10
Clinical Trials by G7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Drugs 21
Clinical Trial Overview of Top Institutes / Government 22
National Institute of Mental Health 22
Clinical Trial Overview of National Institute of Mental Health 22
Massachusetts General Hospital 23
Clinical Trial Overview of Massachusetts General Hospital 23
University of Chicago 24
Clinical Trial Overview of University of Chicago 24
American University of Beirut Medical Center 25
Clinical Trial Overview of American University of Beirut Medical Center 25
Yale University 26
Clinical Trial Overview of Yale University 26
University of South Florida 27
Clinical Trial Overview of University of South Florida 27
University of Sao Paulo 28
Clinical Trial Overview of University of Sao Paulo 28
Hamilton Health Sciences 29
Clinical Trial Overview of Hamilton Health Sciences 29
University of Pennsylvania 30
Clinical Trial Overview of University of Pennsylvania 30
Stanford University 31
Clinical Trial Overview of Stanford University 31
Five Key Clinical Profiles 32
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 51

List of Tables
Trichotillomania Therapeutics, Global, Clinical Trials by Region, 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries, 2014* 8
Trichotillomania Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 9
Trichotillomania Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 10
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 20
Trichotillomania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 22
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 23
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2014* 24
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by American University of Beirut Medical Center, 2014* 25
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 26
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of South Florida, 2014* 27
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 28
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 29
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 30
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 31

List of Figures
Trichotillomania Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 8
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 20
GlobalData Methodology 50


Read the full report:
Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...